Roche Signs $2.8 Billion Alnylam Deal for Hypertension Drug
This article is for subscribers only.
Roche Holding AG will work together with Alnylam Pharmaceuticals Inc. on a potential treatment for high blood pressure in a deal worth as much as $2.8 billion, expanding the Swiss company’s footprint beyond the cancer therapies that long anchored its business.
Roche will pay Alnylam $310 million in cash upfront, together with development, regulatory and sales milestones, the companies said in statements on Monday. If they’re successful in bringing the drug to market, they’ll sell it together in the US while Roche gets exclusive rights in the rest of the world.